Melbourne Mind Medicine Australia Anniversary Screening: Trip of Compassion: A window into psychedelic-assisted psychotherapy
February 19 @ 6:30 pm - 8:30 pm
Don’t miss out – our first screening in September sold out within a few days of being announced. Get your ticket early if you missed out!
By popular demand, Mind Medicine Australia is thrilled to welcome you to our third screening of Trip of Compassion, an acclaimed Israeli documentary on MDMA-assisted psychotherapy for the treatment of Post-Traumatic Stress Disorder (PTSD). Trip of Compassion follows a number of patients participating in clinical trials in Israel, and is the first feature documentary to show footage from within psychedelic-assisted therapy sessions.
“I felt like I went through 15 years of psychological therapy in one night.”
– Patient featured in Trip of Compassion
Following the screening there will be a Q&A panel with Peter Hunt AM, Tania de Jong AM, Renee Harvey and conversation. This will be an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.
“Trip of Compassion is the most compelling movie I’ve seen in the last year!”
– Tim Ferris, acclaimed author and podcaster
More about medicinal MDMA
Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.
Results from Phase 2 clinical trials over the past decade have been so compelling that the Food and Drug Administration (FDA) in the United States recently designated MDMA-assisted psychotherapy as a ‘Breakthrough Therapy’. This designation highlights the FDA’s anticipation that these therapies may offer substantial advantage over current treatments. If forthcoming Phase 3 results confirm these treatments are effective, MDMA-assisted treatment of PTSD may become a prescription medicine as early as 2021 in some jurisdictions.
The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.
More about the panel
Peter Hunt AM
Founder & Chair of Mind Medicine Australia
As an investment banker Peter Hunt AM advised local and multi-national companies and governments in Australia for nearly 35 years. He co-founded and was Executive Chairman of one of Australia’s leading investment banking advisory firms, Caliburn Partnership (now called Greenhill Australia) and continued as Chairman of the Firm after its sale to Greenhill Inc in 2009. Peter is an active philanthropist involved in funding, developing and scaling social sector organisations which seek to create a better and fairer world. Peter was made a member of the General Division of the Order of Australia in the Queen’s Birthday Honours List in 2010 for services to the philanthropic sector.
Tania de Jong AM
LL.B (Hons), GradDipMus
Founder & Deputy Chair of Mind Medicine Australia
Tania de Jong AM is a trail-blazing Australian soprano, award-winning social entrepreneur, creative innovation catalyst, spiritual journey woman, storyteller and global speaker. Tania is one of Australia’s most successful female entrepreneurs and innovators developing 5 businesses and 3 charities over the past 3 decades. She is Founder and Executive Producer of future-shaping events series, Creative Innovation Global. She was appointed a Member of the Order of Australia in June 2008 and named one of the 100 Women of Influence and the 100 Australian Most Influential Entrepreneurs in 2018.
Clinical Psychologist from Imperial College, London
Renee is a Clinical Psychologist has had a long career in the UK as a Consultant in the NHS and more recently as an Honorary Research Fellow at Imperial College London in the study of psilocybin for treatment resistant depression. She has been responsible for leading in service development for people with complex emotional needs across Sussex (UK), establishing three specialist services, including staff appointments, training and supervision, and in clinical delivery in these services.
Dr Nigel Strauss
MBBS, DPM, FRANZCP
Nigel Strauss has been a Consultant Psychiatrist for over 40 years and is the Medical Director of the Millswyn Clinic in South Yarra, a private outpatient psychiatric facility. Dr Strauss is an Honorary Research Fellow within Psychiatry, University of Melbourne and a Member of Scientific Advisory Board, European Foundation for Psychedelic Science. Dr Strauss is also a Member of Scientific and Medical Advisory Board, Australian Institute for Medicinal Cannabis. He has a special interest in medico-legal psychiatry and is employed as a lecturer by AMA Victoria. He has been a Consultant to Worksafe and TAC. Dr Strauss has a special interest in psychedelic medicines and has trained in the UK to work as a psychedelic therapist and is also a MAPS accredited psychedelic therapist.
Support psychedelic research and therapy development
By donating to Mind Medicine Australia, you will be helping us to accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support.
Please click here to make a tax-deductible donation.